Approved HBV Drugs
Approved HBV Drugs
Entecavir Beats Adefovir for Hepatitis B Treatment
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 29 March 2011 10:03
- Written by Liz Highleyman
A meta-analysis of 6 studies found that entecavir (Baraclude) was more effective than adefovir (Hepsera) for treatment-naive HBeAg positive Asian chronic hepatitis B patients. 
Entecavir Approved in Europe for Hepatitis B Patients with Decompensated Liver Diseases
- Details
- Category: Approved HBV Drugs
- Published on Friday, 11 March 2011 09:08
- Written by Bristol-Myers Squibb
Bristol-Myers Squibb announced early this month that the European Commission -- the regulatory authority for the European Union -- approved entecavir (Baraclude) for the treatment of hepatitis B virus (HBV) infection in patients with decompensated liver disease. The U.S. Food and Drug administration (FDA) granted similar approval this past October.
Tenofovir (Viread) Maintains HBV Suppression without Resistance for 4 Years
- Details
- Category: HBV Treatment
- Published on Monday, 01 November 2010 12:48
- Written by Press Release
The nucleotide analog tenofovir (Viread) continued to demonstrate potent activity against hepatitis B virus (HBV) through 4 years, researchers reported at the American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) this week in Boston. In preliminary analyses from Study 102 (HBeAg negative patients) and Study 103 (HBeAg positive patients), HBV viral load remained suppressed, tenofovir was well-tolerated with only a few cases of elevated creatinine (a marker of impaired kidney function), and no drug-resistance mutations were detected. Subgroup analyses from the same studies showed that tenofovir worked well for Asian participants and people with high baseline HBV viral load.
Antiviral Therapy for Chronic Hepatitis B Patients with Decompensated Liver Cirrhosis
- Details
- Category: HBV Treatment
- Published on Tuesday, 16 November 2010 12:48
- Written by Liz Highleyman
Chronic hepatitis B patients with decompensated liver cirrhosis can be treated safely and effectively with antiviral agents, according to a systematic review presented at the recent American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) in Boston. Entecavir (Baraclude) has demonstrated good potency, matching that of lamivudine, but without resistance; newer agents such as tenofovir (Viread) require further study in this population.
FDA Approves Entecavir (Baraclude) for Chronic Hepatitis B Patients with Decompensated Liver Disease
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 19 October 2010 12:49
- Written by Bristol-Myers Squibb
The U.S. Food and Drug Administration announced this week that it has approved the use of entecavir (Baraclude) to treat chronic hepatitis B virus (HBV) infection in people with decompensated liver disease, or liver failure. The expanded indication is supported by results from a Phase 3 trial showing that entecavir was more effective than adefovir (Hepsera) for this hard-to-treat patient population.
More Articles...
- Long-term Entecavir Leads to Regression of Liver Fibrosis in Chronic Hepatitis B Patients
- Long-term Data Show Telbivudine (Tyzeka) Suppresses HBV Viral Load and Leads to HBeAg Clearance in Chronic Hepatitis B Patients
- Should Entecavir (Baraclude) and Tenofovir (Viread) Be First-line Treatment for Chronic Hepatitis B?
- Long-term Adefovir (Hepsera) plus Emtricitabine (Emtriva) vs Adefovir Monotherapy for Chronic Hepatitis B
Web Design and Development by